VentriPoint Diagnostics Ltd. (CVE:VPT) Director Purchases C$15,900.00 in Stock

VentriPoint Diagnostics Ltd. (CVE:VPT) Director Robert Hodgkinson bought 75,000 shares of the company’s stock in a transaction that occurred on Monday, April 22nd. The shares were bought at an average price of C$0.21 per share, for a total transaction of C$15,900.00.

Robert Hodgkinson also recently made the following trade(s):

• On Wednesday, April 24th, Robert Hodgkinson bought 21,000 shares of VentriPoint Diagnostics stock. The shares were bought at an average price of C$0.21 per share, for a total transaction of C$4,410.00.
• On Thursday, April 18th, Robert Hodgkinson bought 36,500 shares of VentriPoint Diagnostics stock. The shares were bought at an average price of C$0.21 per share, for a total transaction of C$7,774.50.

VentriPoint Diagnostics Stock Performance

VPT opened at C$0.21 on Thursday. VentriPoint Diagnostics Ltd. has a 52-week low of C$0.12 and a 52-week high of C$0.36. The firm has a market capitalization of C$32.93 million, a PE ratio of -7.00 and a beta of 0.39. The company has a debt-to-equity ratio of 32.61, a quick ratio of 6.67 and a current ratio of 2.06. The business’s 50-day simple moving average is C$0.25 and its 200 day simple moving average is C$0.24.

VentriPoint Diagnostics Company Profile

Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient's heart chambers; VMS+ software for use in creating three-dimensional model that generates accurate heart volumetric measurements.